New drug duo targets advanced breast cancer in phase 2 trial
NCT ID NCT07591090
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study tests two experimental drugs, AK146D1 and AK112, given together to people with advanced breast cancer that has spread or come back. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 200 adults aged 18 to 75 with HER2-negative breast cancer will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- Heating up tumors: could thermal therapy boost immune attack on breast cancer?